Last reviewed · How we verify
Induction of clinical remission in adults with moderately to severely active Crohn's disease
Approved treatments
- Etrasimod · Pfizer
Etrasimod is an S1P receptor modulator that blocks lymphocyte egress from lymphoid organs, reducing peripheral blood lymphocytes. - Velsipity · Pfizer Inc.
Etrasimod binds S1P receptors 1, 4, and 5, blocking lymphocyte egress from lymphoid organs.
Clinical guidelines
- FDA label — any
VELSIPITY is indicated for the induction of clinical remission in adults with moderately to severely active Crohn's disease. - FDA label — any
VELSIPITY is indicated for the induction of clinical remission in adults with moderately to severely active Crohn's disease.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Induction of clinical remission in adults with moderately to severely active Crohn's disease patent landscape — cliff calendar, originator estates, attackable patents
- Induction of clinical remission in adults with moderately to severely active Crohn's disease treatment landscape brief
- Induction of clinical remission in adults with moderately to severely active Crohn's disease treatment updates RSS
Frequently asked questions about Induction of clinical remission in adults with moderately to severely active Crohn's disease
What drugs treat Induction of clinical remission in adults with moderately to severely active Crohn's disease?
Tracked treatments include Etrasimod, Velsipity.
What is the treatment for Induction of clinical remission in adults with moderately to severely active Crohn's disease?
Standard treatment for Induction of clinical remission in adults with moderately to severely active Crohn's disease includes Etrasimod, Velsipity. See the treatment landscape page for first-line, second-line and salvage options.
What are the treatment guidelines for Induction of clinical remission in adults with moderately to severely active Crohn's disease?
FDA label publishes guidelines for Induction of clinical remission in adults with moderately to severely active Crohn's disease. 2 guideline references tracked.
Related
- Treatment landscape: Induction of clinical remission in adults with moderately to severely active Crohn's disease patent cliff · Induction of clinical remission in adults with moderately to severely active Crohn's disease CI report
- Treatment: Etrasimod · Pfizer
- Treatment: Velsipity · Pfizer Inc.
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing